Cascadian Therapeutics (ONTY) Inactive 10-K2013 FY Annual report

Content analysis

Filed: 13 Mar 14, 12:00am

March 13, 2014

/s/ Julia M. Eastland

Julia M. Eastland,

Chief Financial Officer, Secretary and Vice President of Corporate Development (Principal Financial and Accounting Officer)

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abuse, accretion, Advice, allegedly, alleging, allergy, antibody, appeal, asymptomatic, Attorney, Bachelor, bolster, Boston, capecitabine, cardiac, CI, CNS, College, complaint, conjugate, correlate, CRT, daily, damage, DataMonitor, diarrhea, dismissal, District, draft, dual, duty, EGFR, EMA, emantasine, emtansine, false, fiduciary, fifty, Floor, foster, gastric, Haverford, hoc, HR, identification, IgG, IgM, incidence, interrelated, interrupt, interruption, Kadcyla, KadcylaTM, lapatinib, lawsuit, leadership, led, Love, marker, mg, mild, mismanagement, moderate, modestly, molecular, motion, neratinib, nodal, NOL, Nuvelo, Onyx, opt, payer, Perjeta, pertuzumab, plaintiff, post, predefined, prejudice, pretreated, proportionally, Prothena, Puma, purportedly, QVT, rash, rationale, RECIST, relapse, shareholder, slightly, Society, spent, Stem, symptom, taxane, tecemocide, tecemotide, Ted, Theravance, tool, toxin, trastuzumab, Twenty, Tykerb, tyrosine, underway, underwriter, unissued, unjust, untreated, Western, Xeloda, xenograft

Removed: abolished, added, Aerovance, affiliate, Affymax, analyzing, antibiotic, antiviral, applying, ASC, assay, assumption, attribution, aware, Bayer, began, benchmark, binding, Biogen, borne, Buffalo, capitalization, career, chose, collectability, comparably, concurrently, coordinate, culmination, cum, customer, deposit, died, discontinuation, discontinued, diversified, diversify, diversion, divisional, documented, duration, easy, Enbrel, engineer, exclusivity, executed, executing, exist, existed, expectation, faith, fell, figure, formalized, formulate, GE, harmful, idec, indebted, ineffective, inflammation, influence, innate, inside, instituted, insured, intensive, intent, intermittent, investigation, invoice, invoiced, join, label, laude, launch, lender, lifted, LOI, Lowell, Lucanix, magna, Marketplace, matrix, measuring, myeloma, NovaRx, opened, outflow, owed, Park, participating, peer, perpetual, personalized, pertained, Physiology, plant, played, positive, potentiate, precautionary, prolonged, prominent, promote, promoted, prove, qualify, Qualifying, ratably, reaction, recourse, recruited, reducing, refresher, regular, reinvestment, relied, relinquishing, rest, restate, restructured, retained, returned, reward, rheumatoid, rolling, Roswell, run, separated, shared, shipment, shipped, showing, skill, split, Squibb, steering, stimulation, substance, suspected, Theratope, Topic, unchanged, undelivered, understand, unexpected, utilize, vivo

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ONTY similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

I, Julia M. Eastland, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Oncothyreon Inc. on Form 10-K for the fiscal year ended December 31, 2013, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Oncothyreon Inc.

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Oncothyreon Inc. and will be retained by Oncothyreon Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by Oncothyreon Inc. for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Oncothyreon Inc. specifically incorporates it by reference.